Skip to main content

Table 1 Demographic and clinical characteristics of the patients with NMOSD and CIS/RRMS as well as of healthy controls included in this study

From: Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis

Serum (NGS)

 

NMOSD (n = 20)

CIS/RRMS (n = 20; 16/4)

Healthy controls (n = 20)

p valuea

 Females/males (% female)

18/2 (90)

13/7 (65)

13/7 (65)

0.13

 Median age, y (range)

49.5 (18–75)

33 (20–41)

32 (21–42)

0.004

 Median EDSS (range)

4 (1–9)

1.25 (0–2.5)

–

–

 Immunotherapy (number)

AZA (7)

AZA + S (2)

MTX + Quensyl (1)

GLAT (1)

RTX (6)

MMF (1)

None (2)

Interferon-beta (1)

none (19)

–

–

Whole blood (NGS)

 

NMOSD (n = 11)

CIS/RRMS (n = 60; 50/10)b

Healthy controls (n = 43)c

p value

 Females/males (% female)

10/1 (91)

38/22 (63)

23/20 (53.5)

0.07

 Median age, y (range)

34 (21–75)

31.5 (19–50)

60 (21–83)

0.0003

 Median EDSS (range)

4 (1–9)

1.5 (0–3.5)d

–

–

 Immunotherapy

AZA (3)

AZA + S (1)

MTX + Quensyl (1)

GLAT (1)

RTX (4)

None (1)

Interferon-beta (1)

None (59)

–

–

qRT-PCR validation study

 

NMOSD (n = 19)

CIS/RRMS (n = 19; 15/4)

–

p value

 Females/males (% female)

17/2 (85)

17/2 (85)

–

1.0

 Median age, y (range)

50 (21–75)

41 (23–51)

–

0.1

 Median EDSS (range)

3.75 (1–9)

2 (0–3.5)

–

–

 Immunotherapy (number)

AZA (7)

AZA + S (2)

MTX + Quensyl (1)

GLAT (1)

RTX (5)

MMF (1)

None (2)

GLAT (2)

Interferon-beta (4)

None (13)

–

–

  1. NGS next-generation sequencing, y years, EDSS expanded disability status scale, AZA azathioprine, AZA + S azathioprine and corticosteroids, MTX methotrexate, GLAT glatiramer acetate, RTX rituximab, MMF mycophenolate mofetil, CIS clinically isolated syndrome, RRMS relapsing-remitting multiple sclerosis, NMOSD neuromyelitis optica spectrum disorder
  2. aGender distribution was assessed by 2 × 3 or 2 × 2 Fisher exact test and age differences by Kruskal-Wallis or Mann-Whitney tests
  3. bForty-four of the 60 patients with CIS/RRMS included in this work were recruited in the present study and 16 miRNA expression profiles were from a previous work [25]
  4. cBlood miRNA profiles from the 43 healthy controls were obtained in two previous projects (n = 21 from Keller et al. [25] and n = 22 from Leidinger et al. [29])
  5. dEDSS values were only available for the 44 patients recruited in the present study
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094